Drug intelligence / Profile preview

phenobarbital

Development stage
Approved
Lead developer
Bayer
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Phenobarbital is a long-acting barbiturate used primarily as an anticonvulsant and sedative. It was first introduced in 1912 and remains one of the oldest antiepileptic drugs still in use. Phenobarbital acts by enhancing the activity of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, leading to increased neuronal inhibition and reduced excitability. It is recommended by the World Health Organization for treating certain types of epilepsy—especially in developing countries—and is commonly used for neonatal seizures in developed countries. Other uses include management of insomnia, anxiety disorders, withdrawal from other barbiturates or benzodiazepines, preoperative sedation, and occasionally for status epilepticus when other treatments fail. Phenobarbital can be habit-forming with potential for abuse and withdrawal symptoms upon discontinuation[1][2][5][8].

Brand names
LuminalSolfotonSezaby鲁米那
Other names
phenobarbitonephenobarb苯巴比妥
02

Targets

GABRR (GABA-A receptor subunit rho)Kainate-type ionotropic glutamate receptorAMPAR (AMPA receptor)Nicotinic Acetylcholine ReceptorCaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on phenobarbital.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on phenobarbital.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call